PRCSG News
Abstracts / Posters / Presentations
ACR Convergence 2020
November 5 - 9, 2020
Virtual meeting
JIA-ACR50 Response as a Predictor of Minimal Disease Activity in Patients Aged 2–17 Years With Polyarticular-Course JIA Treated With SC Abatacept. Ruperto N, Brunner H, Berman A, Avila-Zapata F, Horneff G, Alessio M, Becker M, Belot A, Burgos-Vargas R, Boteanu A, Goldenstein-Schainbert C, Scheibel I, Terreri M, Zemel L, Wong R, Askelson M, Nys M, Martini A, Lovell D.
Longitudinal Effectiveness of Abatacept in JIA: Results From an Ongoing JIA Registry. Lovell DJ, Brunner HI, Tzaribachev N, Morgan E, Simonini G, Griffin TA, Alexeeva E, Bohnsack J, Zeft A, Horneff G, Vehe R, Stanevica V, Tarvin S, Trachana M, Huber A, Orban I, Dare J, Foeldvari I, Quartier P, Dominique A, Kou TD.
Poster THU0503: PLUTO Trial: Sensitivity Analyses of SRI4 response with Belimumab vs Placebo in Paediatric Patients With Childhood-Onset Systemic Lupus Erythematosus.
OP0291: Tofacitinib for the treatment of polyarticular course juvenile idiopathic arthritis: results of a Phase 3, randomised, double-blind, placebo-controlled withdrawal study.
Poster THU0497: Maintenance Of Minimal Disease Activity Or Inactive Disease Status And Patient-Reported Outcomes In Individual Paediatric Patients With Juvenile Idiopathic Arthritis Treated With Subcutaneous Abatacept.
Poster SAT0505: Pluto Trial of Intravenous Belimumab in Paediatric Patients with Childhood-Onset Systemic Lupus Erythematosus (cSLE): Patient Responses Over Time.
************************************************************************************************************************
August 2020 - Canakinumab improves systemic juvenile idiopathic arthritis regardless of fever Healio
October 2019 - Accelerating Drug Development for Polyarticular Juvenile Idiopathic Arthritis (pJIA). View the speaker slides and video recordings.
April 2019 - FDA approves Benlysta (belimumab) for children with lupus who are five years old or above